NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis.

Product information

CAS Number: 2389235-01-0

Molecular Weight: 399.44

Formula: C24H21N3O3

Chemical Name: 2-{3, 5-bis[(6-methylpyridin-2-yl)oxy]phenoxy}-6-methylpyridine

Smiles: CC1C=CC=C(N=1)OC1=CC(=CC(=C1)OC1=CC=CC(C)=N1)OC1C=CC=C(C)N=1

InChiKey: OPUQKVNCXCWRLR-UHFFFAOYSA-N

InChi: InChI=1S/C24H21N3O3/c1-16-7-4-10-22(25-16)28-19-13-20(29-23-11-5-8-17(2)26-23)15-21(14-19)30-24-12-6-9-18(3)27-24/h4-15H,1-3H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 135 mg/mL (337.97 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels. NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract.

Products are for research use only. Not for human use.